Wang, Feng-Hua <br/><br/>
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.  [electronic resource] 

 -  Cancer  Oct 2017 
 - 3986-3994 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.30845  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Squamous Cell--drug therapy<br/>China<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Esophageal Neoplasms--metabolism<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Lymphotoxin-alpha--adverse effects<br/>Male<br/>Middle Aged<br/>Receptors, Tumor Necrosis Factor, Type II--blood<br/>Recombinant Proteins--adverse effects